Leadership Lessons is a monthly column from executives and thought leaders regarding best practices they use at their organizations to develop managers and leaders at all levels of the organization.
Many potential innovations die not because the idea is bad, but because innovators can’t win support to turn their ideas into reality. We call it the innovator’s paradox: the more groundbreaking your idea, the greater the risk, and the harder it is to win support.
Across a dozen fields – from social psychology to endocrinology to chronobiology – researchers are assembling a new science of breaks. Their main finding: Leaders and their teams should be taking more breaks.
Many leaders are increasingly facing the threat of their core business being encroached upon by upstarts outside of their industry. So, what differentiates the top innovative companies from those in the middle?
To help identify why someone might say no to your requests, you can refer to the acronym GREAT. GREAT outlines the five most common reasons why someone might say no to your request and helps you strategize how to get to yes.
How do you create a high performing, resilient organization in times of stress and uncertainty? By developing your own internal capacity following the principles of “conscious leadership,” one of the four key tenets of “conscious capitalism.”
History teaches us that disruptive change is bad news for even the best run incumbents. How can executives confront the dilemmas of disruption?
Your attention is your most valuable asset. Here’s how you can spend it wisely.
The fate of your business rests largely on the willingness of individuals to choose to invest their best discretionary effort in your company’s cause — to dig deep for innovative ideas, to imagine solutions outside any box, to perceive subtle shifts and faint signals.
“Superbosses” are known in their industries not merely for their innovation and financial success, but for spawning a generation of leaders.
Bigger might not be better when it comes to getting access to more diverse perspectives.
For 30 years I have been researching midsized, little-known global market leaders. I often observe five common traits in these leaders.
A big part of the innovation challenge for large pharma companies is that while researchers are very good at technical innovation, the business end is not.
It’s easy to say we value different perspectives. It is quite another thing to really mean it, especially when it comes to views that feel dangerous, unscientific, and just plain wrong.
Here’s what employers concerned about healthcare, and for that matter, productivity and employee retention, need to do.
Robert Hariri, M.D., Ph.D., discusses how he became friends with life coach Tony Robbins, and why Robbins decided to invest in his company.
A preview of an October 2109 issue article that discusses the results of the 2018 MassNextGen initiative that provides funding and coaching support to early-stage life sciences companies started by females.
Robert Hariri, M.D., Ph.D., CEO of Celularity Therapeutics, shares how a biopharmaceutical industry CEO has come to know Hollywood celebrities.
Chris Anselmo provides his thoughts as a first time panelist and attendee of the 2019 BIO International Convention and Conference, Philadelphia, PA, June 3 - 6.
While the annual BIO International Convention and Conference has much in common with the annual J.P. Morgan Healthcare Conference, first time attendee of BIO, Matt Pillar, quickly picks up on key points of differentiation at BIO 2019 this year in Philadelphia, PA, June 3 - 6.